NO975692L - Bifosfonater som forhindrer tap av benmasse i forbindelse med immunsuppressiv terapi - Google Patents

Bifosfonater som forhindrer tap av benmasse i forbindelse med immunsuppressiv terapi

Info

Publication number
NO975692L
NO975692L NO975692A NO975692A NO975692L NO 975692 L NO975692 L NO 975692L NO 975692 A NO975692 A NO 975692A NO 975692 A NO975692 A NO 975692A NO 975692 L NO975692 L NO 975692L
Authority
NO
Norway
Prior art keywords
bone loss
biphosphonates
connection
immunosuppressive therapy
prevent bone
Prior art date
Application number
NO975692A
Other languages
English (en)
Other versions
NO975692D0 (no
Inventor
Anastasia G Daifotis
Ashley J Yates
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO975692L publication Critical patent/NO975692L/no
Publication of NO975692D0 publication Critical patent/NO975692D0/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Bisfosfonat, spesielt alendronat, kan forhindre eller avstedkomme behandling av tap av benmasse forbundet med immun- suppressiv terapi, enten den immunsup- ; pressive terapi er forbundet med en organtransplantasjon eller ikke.
NO975692A 1995-06-06 1997-12-05 Bifosfonater som forhindrer tap av benmasse i forbindelse med immunsuppressiv terapi NO975692D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/471,466 US5616571A (en) 1995-06-06 1995-06-06 Bisphosphonates prevent bone loss associated with immunosuppressive therapy
PCT/US1996/008398 WO1996039151A1 (en) 1995-06-06 1996-06-03 Bisphosphonates prevent bone loss associated with immunosuppressive therapy

Publications (2)

Publication Number Publication Date
NO975692L true NO975692L (no) 1997-12-05
NO975692D0 NO975692D0 (no) 1997-12-05

Family

ID=23871741

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975692A NO975692D0 (no) 1995-06-06 1997-12-05 Bifosfonater som forhindrer tap av benmasse i forbindelse med immunsuppressiv terapi

Country Status (14)

Country Link
US (1) US5616571A (no)
EP (1) EP0831844A4 (no)
JP (1) JPH11507044A (no)
KR (1) KR19990022380A (no)
CA (1) CA2223400A1 (no)
CZ (1) CZ288906B6 (no)
EA (1) EA000964B1 (no)
HU (1) HUP9900886A3 (no)
IL (1) IL122149A (no)
NO (1) NO975692D0 (no)
NZ (1) NZ310000A (no)
PL (1) PL323797A1 (no)
SK (1) SK163797A3 (no)
WO (1) WO1996039151A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122479C (en) * 1991-11-22 1998-08-25 Richard John Dansereau Risedronate delayed-release compositions
KR19980702210A (ko) * 1995-02-17 1998-07-15 폴락 돈나 엘 비척추골 골절의 위험률을 감소시키는 방법
EP1007054A4 (en) * 1996-10-04 2000-07-19 Merck & Co Inc LIQUID ALENDRONATE FORMULATIONS
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
AU741818C (en) * 1997-07-22 2003-01-09 Merck Sharp & Dohme Corp. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
AU6427599A (en) * 1998-10-15 2000-05-01 Merck & Co., Inc. Methods for stimulating bone formation
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
EP1175433B1 (en) 1999-05-04 2005-08-03 Strakan International Limited Androgen glycosides and androgenic activity thereof
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
ATE383863T1 (de) * 2000-03-02 2008-02-15 Univ Pittsburgh Kombinationschemotherapie
NZ527157A (en) * 2001-03-01 2005-04-29 Emisphere Tech Inc Compositions for delivering bisphosphonates
JP2005531532A (ja) * 2002-04-05 2005-10-20 メルク エンド カムパニー インコーポレーテッド アレンドロナートおよびビタミンd製剤を用いる骨吸収阻害法
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
KR20070121759A (ko) * 2005-03-17 2007-12-27 엘란 파마 인터내셔널 리미티드 나노입자형 비스포스포네이트 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8530603D0 (en) * 1985-12-12 1986-01-22 Leo Pharm Prod Ltd Chemical compounds
SK74594A3 (en) * 1991-12-17 1995-01-12 Procter & Gamble Pharma Treatment for treating of osteoporosis
DK0648120T3 (da) * 1992-06-30 1998-01-19 Procter & Gamble Pharma Anvendelse af phosphonater til behandling af osteoporose
US5578593A (en) * 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
EP0675723A4 (en) * 1992-12-23 1998-08-05 Merck & Co Inc BIPHOSPHONATE / ESTROGEN THERAPY FOR TREATING AND PREVENTING BONE LOSS.
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
NZ272608A (en) * 1994-07-22 2000-05-26 Lilly Co Eli Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
WO1996007418A1 (en) * 1994-09-09 1996-03-14 The Procter & Gamble Company Phosphonates and parathyroid hormone for osteoporosis

Also Published As

Publication number Publication date
IL122149A0 (en) 1998-04-05
SK163797A3 (en) 1998-07-08
HUP9900886A3 (en) 2002-04-29
EA199800011A1 (ru) 1998-06-25
JPH11507044A (ja) 1999-06-22
KR19990022380A (ko) 1999-03-25
US5616571A (en) 1997-04-01
AU6030996A (en) 1996-12-24
HUP9900886A2 (hu) 2001-04-28
CA2223400A1 (en) 1996-12-12
NO975692D0 (no) 1997-12-05
CZ389897A3 (cs) 1998-07-15
EA000964B1 (ru) 2000-08-28
EP0831844A1 (en) 1998-04-01
EP0831844A4 (en) 1998-12-30
WO1996039151A1 (en) 1996-12-12
PL323797A1 (en) 1998-04-27
NZ310000A (en) 2000-07-28
CZ288906B6 (cs) 2001-09-12
IL122149A (en) 2001-03-19
AU696097B2 (en) 1998-09-03

Similar Documents

Publication Publication Date Title
NO975692L (no) Bifosfonater som forhindrer tap av benmasse i forbindelse med immunsuppressiv terapi
CA2214122A1 (en) Composite membrane
WO1998032412A3 (en) Bistable spring construction for a stent and other medical apparatus
BR0203650A (pt) Estentor de auto-articulação
DK0650374T3 (da) Anvendelse af et porøst materiale på basis af calciumcarbonat som bærer for en vækstfaktor ved fremstillingen af et bioreso
ATE397005T1 (de) Sialyl-lewisa und sialyl-lewisx epitope analoge
NO982311L (no) Sammensetninger og fremgangsmÕter for forhindring og behandling av oral muscositt
MX9805628A (es) Imidazoles novedosos substituidos con cicloalquilo.
TR28091A (tr) Bulusun valfini ve kazanini iceren, seyyar müsterek jeneratör tertibati.
AU2003298880A1 (en) Coating for implantable devices and a method of forming the same
WO1993020757A3 (en) Vascular implant system
WO1999016416A3 (de) Beschichtete medizinische implantate, verfahren zu ihrer herstellung und ihre verwendung zur restenoseprophylaxe
CA2218289A1 (en) Cd45rb binding compounds for the prevention of transplant rejection
NO964539L (no) Kollagen-preparat for kontrollert avgivelse av virkestoffer
EP1356818A3 (de) Medikament, insbesondere zur Modulation der Immunantwort bei der Bekämpfung von Viren, Tumoren, Bakterien und Parasiten
BG104117A (en) Universally applicable blood plasma
ATE543451T1 (de) Bioabsorbierbare, osteogenetische knochenplatte
EP0771551A3 (en) Prosthetic bearing element and implant incorporating such an element
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
TW330244B (en) The optical system with variable magnified rate
AU3170500A (en) Method for preparing an antimicrobial composition
PT1141069E (pt) Composicao de revestimento
PT1126853E (pt) Distribuicao controlada de anti-depressivos
MX9709906A (es) Uso de bisfosfonatos para preparar composiciones para prevenir perdida de hueso asociada con terapia inmunosupresora.
NO951475D0 (no) Kunstoffbane som forhindrer eller i det minste vesentlig reduserer vanndampdiffusjon

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application